# Sutro Biopharma

Source: https://onco.cc/companies/sutro-biopharma/  
OnCo record `sutro-biopharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Cell-free protein synthesis ADC company that refocused on exatecan and dual-payload ADCs, deprioritising its folate-receptor ADC luveltamab.

## Summary

STRO-004 (tissue factor, DAR8 TOP1 payload) is the lead, with first clinical data expected mid-2026; STRO-227 is a DAR10 dual-payload PTK7 ADC (MMAE DAR2 + TOP1 DAR8) with IND planned 2026. Luveltamab tazevibulin (FRα) development stopped pending a partner. Site-specific conjugation via non-natural amino acids (XpressCF).

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: South San Francisco, CA
- Type: biotech
- Website: https://www.sutrobio.com
- Ticker: STRO

## Sources

- AACR 2026 pipeline data: https://www.biospace.com/press-releases/sutro-biopharma-presents-promising-preclinical-data-across-its-pipeline-of-next-generation-single-and-dual-payload-adc-programs-at-aacr-2026

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Dual-payload ADC](https://onco.cc/technologies/dual-payload-adc/), [Site-specific conjugation & linker chemistry](https://onco.cc/technologies/site-specific-conjugation/)
- targets: [Folate receptor alpha](https://onco.cc/targets/folr1/), [Tissue factor](https://onco.cc/targets/tissue-factor/)
- drugs: [Luveltamab tazevibulin](https://onco.cc/drugs/luveltamab-tazevibulin/)
- bottlenecks: [Acquired resistance to every therapy](https://onco.cc/bottlenecks/b-resistance/)
- ideas: [Use antibodies to deliver protein-destroying drugs into the right cells](https://onco.cc/ideas/idea-bio1-antibody-degrader-conjugates/)
- trials: [REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1](https://onco.cc/trials/nct05870748/)

---
JSON: https://onco.cc/api/v1/entities/sutro-biopharma.json